Shenzhen New Industries Biomedical Engineering Co., Ltd.
Символ: 300832.SZ
SHZ
68.37
CNYПазарна цена днес
35.0402
Съотношение P/E
1.8688
Коефициент PEG
53.72B
MRK Cap
- 0.01%
Доходност на DIV
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832-SZ) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3404.2 | 3297.1 | 3424.1 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 2356 | 2813.7 | 2806.5 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 712.4 | 506.6 | 314.3 | ||||||||||||
balance-sheet.row.inventory | 0 | 916.8 | 839.3 | 645.4 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 30.5 | 179.3 | 113.4 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 5064 | 4822.4 | 4497.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1446.6 | 1325.5 | 1134.3 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 169.5 | 172.5 | 94.6 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 169.5 | 172.5 | 94.6 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 1347.8 | -2456 | -2669.6 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 37.9 | 22.9 | 12.1 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 156.7 | 3127.4 | 3066.9 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 3158.5 | 2192.2 | 1638.4 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 0 | 8222.5 | 7014.6 | 6135.5 | ||||||||||||
balance-sheet.row.account-payables | 0 | 127 | 176.7 | 171.4 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 1.7 | 1.3 | 1.4 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 120.4 | 79.5 | 69.9 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 3.5 | 0.9 | 0.9 | ||||||||||||
Deferred Revenue Non Current | 0 | 33.1 | 5.8 | 6.6 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 371.3 | 297 | 3.7 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 53.6 | 31.1 | 15.6 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 3.5 | 0.9 | 0.9 | ||||||||||||
balance-sheet.row.total-liab | 0 | 645 | 615.1 | 523.5 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0 | 785.7 | 786.1 | 786.7 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 4980.7 | 3874.3 | 3108.5 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 551.5 | 496.7 | 453.4 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1226.5 | 1242.4 | 1263.4 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 7544.4 | 6399.5 | 5612 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 8222.5 | 7014.6 | 6135.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 0 | 7544.4 | 6399.5 | 5612 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 3703.7 | 357.6 | 136.9 | ||||||||||||
balance-sheet.row.total-debt | 0 | 5.2 | 2.2 | 2.2 | ||||||||||||
balance-sheet.row.net-debt | 0 | -1043.1 | -481.2 | -615.3 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 1653.7 | 1327.9 | 973.7 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 179.2 | 116.5 | 97 | ||||||||||||
cash-flows.row.deferred-income-tax | 0 | 4.8 | 3.2 | 18.3 | ||||||||||||
cash-flows.row.stock-based-compensation | 0 | -688 | -80.7 | 93.9 | ||||||||||||
cash-flows.row.change-in-working-capital | 0 | -329.7 | -304.8 | -354 | ||||||||||||
cash-flows.row.account-receivables | 0 | -277.2 | -240.2 | -154.7 | ||||||||||||
cash-flows.row.inventory | 0 | -136.5 | -229.9 | -227.7 | ||||||||||||
cash-flows.row.account-payables | 0 | 84 | 162.1 | 10 | ||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 3.2 | 18.3 | ||||||||||||
cash-flows.row.other-non-cash-items | 0 | 678.2 | -99.6 | -55.6 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -322.2 | -403.2 | -342.9 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | 0.1 | 0.7 | 0.2 | ||||||||||||
cash-flows.row.purchases-of-investments | 0 | -7509.5 | -10196.3 | -9617.8 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 7461 | 10010.1 | 9036 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -5 | 0 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -370.6 | -593.7 | -924.6 | ||||||||||||
cash-flows.row.debt-repayment | 0 | -16.3 | -4.1 | -3.6 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 25.7 | 0 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -21.6 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | -550 | -471.8 | -413.4 | ||||||||||||
cash-flows.row.other-financing-activites | 0 | 1.8 | -25.7 | 129.6 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -568.6 | -497.4 | -287.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 8.7 | -9.1 | -14 | ||||||||||||
cash-flows.row.net-change-in-cash | 0 | 564.8 | -137.9 | -452.8 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 1048.3 | 478.1 | 616 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 483.4 | 616 | 1068.8 | ||||||||||||
cash-flows.row.operating-cash-flow | 0 | 1498.1 | 962.4 | 773.2 | ||||||||||||
cash-flows.row.capital-expenditure | 0 | -322.2 | -403.2 | -342.9 | ||||||||||||
cash-flows.row.free-cash-flow | 0 | 1175.9 | 559.2 | 430.3 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 3914.4 | 3047 | 2545.4 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 1170.3 | 906.2 | 734.3 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 2744.1 | 2140.8 | 1811.1 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | -2.1 | -41.4 | 109.1 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 1006 | 772.6 | 723.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 2176.3 | 1678.8 | 1458.2 | ||||||||||||
income-statement-row.row.interest-income | 0 | 15.4 | 5.4 | 3.7 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 0.4 | 0.3 | 0.2 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 155 | -2.4 | -1.9 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -2.1 | -41.4 | 109.1 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 155 | -2.4 | -1.9 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 0.4 | 0.3 | 0.2 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 179.2 | 112.8 | 68.8 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | 1738.1 | 1503.6 | 1137.4 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | 1893.1 | 1501.2 | 1135.5 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 239.4 | 173.3 | 161.8 | ||||||||||||
income-statement-row.row.net-income | 0 | 1653.7 | 1327.9 | 973.7 |
Често задавани въпроси
Какво е Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) общи активи?
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) общите активи са 8222488843.000.
Какъв е годишният приход на предприятието?
Годишните приходи са N/A.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е 1.550.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е 1.550.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.424.
Какъв е общият приход на предприятието?
Общият приход е 0.470.
Каква е Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е 1653653244.000.
Какъв е общият дълг на фирмата?
Общият дълг е 5179720.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 1006019450.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 0.000.